In Brazil, confirmed Rifampicina Resistant/Multi-Drug Resistant Tuberculosis (RR-/MDR-TB) cases are projected to increase steadily from 2024 to 2028. The data shows an annual rise in confirmed cases, with a Compound Annual Growth Rate (CAGR) of approximately 1.66% over five years. In 2023, the cases stood at approximately 1.16 thousand.
The year-on-year growth rates exhibit a consistent rise: 2.54% from 2024 to 2025, 1.65% from 2025 to 2026, 2.44% from 2026 to 2027, and 1.59% from 2027 to 2028. This trend indicates a persistent challenge in controlling RR-/MDR-TB in Brazil in the near future.
Future trends to watch for include advancements in diagnostic technologies, the effectiveness of new treatments, and public health interventions to curb this steady increase. Monitoring these factors will be crucial in managing and potentially reversing the upward trend in RR-/MDR-TB cases.
